NEUROTROPE, INC. (OTCMKTS:NTRPD) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement.
On November 29, 2018, Neurotrope Bioscience, Inc. (“Neurotrope Bioscience”), the operating subsidiary of Neurotrope, Inc. (the “Company’), on the one hand, and Cognitive Research Enterprises, Inc., formerly known as Blanchette Rockefeller Neurosciences Institute (“CRE”), and NRV II, LLC (“NRV II”), on the other hand, entered into a second amendment (the “Amendment”) to the Amended and Restated Technology License and Services Agreement, dated February 4, 2015, as amended on November 12, 2015, between such parties (the “TLSA”) to which CRE granted rights in certain technology to Neurotrope Bioscience. Capitalized terms not otherwise defined herein have the meanings set forth in the TLSA.
Under the Amendment, the parties agreed to modify the prosecution and maintenance obligations to provide that Neurotrope Bioscience shall have the sole and exclusive right and obligation to apply for, file, prosecute and maintain patents and applications for the Licensed IP. Neurotrope Bioscience agreed to pay to CRE and NRV II $10,000 as consideration for the Amendment. The Amendment became effective on the date on which Neurotrope Bioscience paid to CRE all outstanding invoices and accrued expenses associated with the Licensed IP, which were included on a schedule to the Amendment.
The foregoing description of the Amendment is qualified in its entirety by the full text of the Amendment, the form of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
The following exhibit is filed herewith:
(d) Exhibits.
Neurotrope, Inc. ExhibitEX-10.1 2 tv508407_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 FORM OF SECOND AMENDMENT TO THE AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENT This Second Amendment to the Amended and Restated Technology License and Services Agreement,…To view the full exhibit click here
About NEUROTROPE, INC. (OTCMKTS:NTRPD)
Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer’s disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD.
